And why ?????????????. Breast cancer: -in the Netherlands 10.000 new cases/year -incidence has doubled since 1940, now 1000/10 6 women/year -30 % of all.

Slides:

Advertisements

Similar presentations

Breast Cancer Patient Issues in Family Practice: An Interactive Session.

Advertisements

SABCS 2011 BOLERO-2 Updated Results

Progress Against Breast Cancer

BIG-TRANSBIG HQ– Used with permission TRANSLATING MOLECULAR KNOWLEDGE INTO EARLY BREAST CANCER MANAGEMENT Fatima Cardoso, MD TRANSBIG Scientific Director.

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Spatial Separation of HLA-DM/HLA-DR Interactions within MIIC and Phagosome- Induced Immune Escape Wilbert Zwart, Alexander Griekspoor, Coenraad Kuijl,

Breast cancer chemoprevention in the high-risk patient

Breast Cancer Systemic Therapy for Early Stage Disease

Endocrine resistant hormone positive metastatic breast cancer

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Breast Cancer An Overview Dr. Christina Tzagarakis-Foster November 9, 2006.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.

Laura J. Van ‘t Veer Helen Diller Family Comprehensive Cancer Center University of California, San Francisco Biology of disease Who is at risk for what.

Breast Cancer and Hormone Therapy Student: Lisa Kiesow Faculty: Dr. Nancy Bachman Abstract Breast cancer is the most commonly occurring cancer in women.

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Breast Cancer Research Presented by Manish Modi Manish Modi Stevens Institute of Technology REU SUMMER 2005.

Personalized Breast Cancer Care Sunil Patel, MD Medical Oncology and Hematology Collom and Carney Clinic.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

2012 Navigating Hormonal Therapy Paula D. Ryan, MD, PhD Associate Professor, Medical Oncology April 29, 2012.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

LETROZOLE- AN ANTI BREAST CANCER DRUG LOC HUA CHEMISTRY 12B- SEMINAR # 11.

Breast Cancer By: Christen Scott.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,

Breast Cancer. Introduction  As old as 1600 BC  Emerges from inner lining of milk ducts  Or the lobules that supply milk  Types:  DCIS  LCIS.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Copyright © 2010, Research To Practice, All rights reserved. Current Clinical and Future Developmental Paradigms Involving Molecular Pathways in Breast.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

Heterogeneity in hormone receptor positive breast cancer

ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Breast Cancer Mechanisms 1. 2 Her

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

JOURNAL OF CLINICAL ONCOLOGY 2012; vol 30 Thomas Bachelot, Ce´line Bourgier, Claire Cropet, Isabelle Ray-Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie.

BREAST CANCER Anterpreet Neki, MD , MS

Biology and Treatment of Breast Cancer

Challenges for the treatment of breast cancer

AROMATASE INHIBITORS.

Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon

Metastatic Breast Cancer

Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*

Conclusions- Discussion

Aromatase Inhibitors. Aromatase Inhibitors.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Endocrine Therapy for Metastatic Breast Cancer

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

Treatment of HR+ Breast Cancer: A Clinical Update

Simona Borštnar, MD, PhD Division of Medical Oncology

Selective estrogen receptor modulation

Effect of Obesity on Prognosis after Early Breast Cancer

Introduction Advanced Hormone Receptor-Positive Breast Cancer

ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.

Volume 5, Issue 6, Pages (June 2004)

Principles and Practice of Radiation Therapy

Presentation transcript:

and why ?????????????

Breast cancer: -in the Netherlands new cases/year -incidence has doubled since 1940, now 1000/10 6 women/year -30 % of all cancers in women -life time risk is 8-12% -in 50% of women with primary tumors occult metastases occur -death rate: 40% in node-negative 70% in node-positive nearly 100% in metastatic disease hereditary 5-10%, involvement BRCA-1, BRCA-2 and CHEK-2 in men: incidence 1% of that of women.

Hormonale behandeling bij borstkanker Remmers van de ER werking: Anti-oestrogenen borst bot endometrium endotheel SERM: tamoxifen – + + – selective ER modulatorraloxifen – + – – SERD ( selective ER downregulator) = full-anti-oestrogenen: ICI (Faslodex=Fulvestrant) doet ER afbreken. Remmers van de oestrogeen aanmaak: Aromatase remmers Nonsteroidale: Anastrazole (Arimidex) en Letrozole (Femara) Steroidale : Exemestane(Aromasin)

Ligands and anti-estrogens

Endocrine treatment options of breast cancer After Robertson et al, EJC, 41, 346, 2005.

ER- ER+ tamoxifen treatment Fulvestrant, Aromatase inhibitors effect of anti-estrogen treatment on recurrence in breast cancer recurrences tumor progressie veroorzaakt door genetische chaos

ER  -DESER  - raloxifene agonistantagonist cofactor

FRET Fluorescence Resonance Energy Transfer

Profile of anti-estrogen sensitivity by FRET sensitive insensitive resistant

Hypothetical scheme of anti-estrogenic treatment of breast cancer ER positive tumor truly positive tumor, ER dependent : or not chemotherapy PKAMAPK treatment tamoxifen ICI or resveratrol fulvestrant raloxifene Individual treatment based on modification of the Estrogen Receptor

Acknowledgements Tumor Biology Alexander Griekspoor Wilbert Zwart Lennert Janssen Astrid Balkenende Desiree Verwoerd Els Groeneveld Jacques Neefjes Rob Michalides Clinic Sabine Linn Pathology Hans Peterse Elly Mesman Ellen Riem Statistics Harm van Tinteren FRET Kees Jalink Microarray Arno Floore Arno Velds Laura van ‘t Veer CLSM Lauran Oomen Lenny Brocks FACS Anita Pfauth Frank van Diepen Monoclonal Antibody Upstate Biotechnology Inc. Anti-estrogens Michel Renoir, Geneva Claude Labrie, Quebec Organon GSK